Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pharmacological treatment of depression in women with breast cancer: a systematic review

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mortality after contralateral breast cancer in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Every exercise bout matters: linking systemic exercise responses to breast cancer control

    Research output: Contribution to journalReviewResearchpeer-review

  3. Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Nationwide cross-sectional study of Danish surgeons' professional use of social media

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dynamic contrast-enhanced EUS for quantification of tumor perfusion in colonic cancer: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The objective of this study is to review the literature on pharmacological treatment of depression in women with breast cancer. According to the PRISMA guidelines, we conducted a systematic review of randomized, controlled clinical trials and open label prospective studies on antidepressants effects on depression in women with breast cancer up to January 14, 2013. In this analysis, a total of 213 studies were identified, and six studies met the inclusion criteria. Of the six studies, three were placebo-controlled randomized controlled clinical trials with fluoxetine, a selective serotonin reuptake inhibitor; and Mianserin—a noradrenergic and specific serotonergic antidepressant. Both studies found that fluoxetine and mianserin significantly improved depressive symptoms and quality of life (QOL) compared with placebo. Conversely, desipramine, a tricyclic antidepressant, and the SSRI, paroxetine, showed no significant effects on depression compared with placebo. A double-blind, parallel group study comparing a tricyclic antidepressant, amitriptyline, and paroxetine showed a significant and comparable improvement in depression and QOL. Two open label, prospective studies found that escitalopram and the norepinephrine reuptake inhibitor, reboxetine, significantly improved depression and QOL compared with baseline values. In conclusion, depression is a clinical problem in patients with breast cancer. Pharmacological treatment with antidepressants may improve depression and QOL. However, the evidence is limited, and the studies are too heterogeneous to recommend one regimen or drug over another. Further antidepressant studies are needed to guide depression treatment in patients with breast cancer.
Original languageEnglish
JournalBreast cancer research and treatment
Volume141
Issue number3
Pages (from-to)325-30
Number of pages6
ISSN0167-6806
DOIs
StatePublished - Oct 2013

ID: 42220516